Organization · Venture Capital
Capital Cell
Capital Cell is Europe's first dedicated equity crowdfunding platform for biotechnology and life sciences, based in Barcelona. It connects private investors with early-stage biotech startups, emphasizing expert vetting of investment opportunities.
Overview
What Capital Cell does
What Capital Cell is
Capital Cell is Europe's first dedicated equity crowdfunding platform for biotechnology and life sciences, based in Barcelona. It connects private investors with early-stage biotech startups, emphasizing expert vetting of investment opportunities.
How it participates in the startup ecosystem
The current public profile supports funder and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2015
- Approximate age
- About 11 years
- Structured capabilities
- Funder · Publisher
- Last reviewed
- March 27, 2026
Official channels
Find Capital Cell elsewhere
Open the official website or a supported primary organization account.
Capability profile
Capital Cell as a funder
Investment thesis
Capital Cell democratizes access to high-impact investments in biotechnology and life sciences, connecting private investors with early-stage startups in these sectors.
Focus narrative
Capital Cell focuses on investing in biotechnology and life sciences companies through equity crowdfunding. The platform enables investors to participate in funding rounds for startups in these sectors, emphasizing a rigorous vetting process through its BioExpert Network of over 800 opinion leaders and biomedical experts.
Value beyond capital
Capital Cell adds value to its portfolio companies by providing access to a network of biomedical experts who offer scientific due diligence, enhancing the credibility of the startups. Additionally, the platform democratizes investment opportunities, allowing startups to raise capital from a diverse pool of investors.
Terms and economics
- Typical check
- $100
Focus and fit
- Stages
- Seed
- Regions
- EuropeUnited Kingdom
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 120
- Recorded notable exits
- Bionure
Portfolio context
As of 2024, Capital Cell has completed over 120 funding rounds, with a total investment of approximately €107 million across more than 120 companies. Notable portfolio companies include Bionure, which raised early capital on Capital Cell and later signed a billion-dollar licensing agreement, as well as Ability Pharmaceuticals and Arcis Biotechnology.
Capability profile
Capital Cell as a publisher
Editorial focus
Capital Cell is an alternative investment platform that focuses on early-stage biotechnology and life sciences companies. Founded in 2015 in Barcelona, Spain, it aims to democratize access to high-impact investments in the life sciences sector, allowing individuals to contribute to advancements in human health. The organization employs a rigorous selection process, accepting only about 3% of the companies that apply for investment, and leverages a network of over 3,500 experts to analyze investment opportunities.
Audience value
Capital Cell provides a unique opportunity for individual investors to participate in the biotech sector, which has traditionally been gated by institutional investors. By leveraging a proprietary BioExpert Network for scientific due diligence, the platform ensures that investors have access to vetted and promising investment opportunities.
Format and cadence
- Content formats
- blog
- Primary platform
- Capital Cell's website
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Investors · Founders
- Regions
- EuropeUnited Kingdom
Flagship work and coverage
Flagship properties
Capital Cell operates as Europe's first dedicated life sciences equity crowdfunding platform, connecting private investors with early-stage biotech and healthtech startups. The platform has facilitated over EUR 107 million in investments across 120+ companies.
Notable coverage
Capital Cell has been recognized as one of the most active biotech investors in Europe, with notable portfolio companies such as Bionure, which raised early capital on the platform and later signed a billion-dollar licensing agreement with a pharmaceutical company.
Common questions
What to know about Capital Cell
Upseed classifies Capital Cell under the Venture Capital organization type. Its current public profile includes funder and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.